Juva Life Launches Preclinical Comparative Study to Evaluate Anti-Inflammatory Properties of Candidate JUVA-019 in Conjunction With Other Well-Known Cannabinoids
Juva Life Launches Preclinical Comparative Study to Evaluate Anti-Inflammatory Properties of Candidate JUVA-019 in Conjunction With Other Well-Known Cannabinoids
Cannabis and Life Sciences Company Initiates Internal Study Comparing Anti-Inflammatory Properties of Candidate JUVA-019 When Combined With Cannabinoids Such as THC and CBD
VANCOUVER, British Columbia, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a life sciences portfolio company with operations in cannabis production and distribution as well as pharmaceutical research and development, announced today that it has launched a pre-clinical comparative study on its proprietary molecular candidate JUVA-019, comparing its anti-inflammatory properties as a standalone compound and in combination with well-known cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD). The goal of the study is to determine if Juva will advance JUVA-019 as a standalone compound, or if it will combine with other cannabinoids as a drug candidate with anti-inflammatory properties.
The study will be conducted in-house via Juva’s research team, led by Dr. Sanjeev Gangwar, Ph.D., who has an extensive background in pharmaceutical research and development. The study will follow a similar protocol used previously to identify JUVA-019. JUVA-019 will be evaluated in combination with multiple well-known cannabinoids, one at a time, and then all together to evaluate their inhibition of IL1-beta and TNF-alpha, which are some of the biomarkers in the body that indicate inflammation. The results will then be compared to the results from JUVA-019, identifying which combination or standalone compound is more effective at inhibition of multiple cytokines implicated in inflammation.
“This is an important step in the research protocol of our pharmaceutical program on JUVA-019,” said Doug Chloupek, CEO and Founder of Juva. “It’s widely believed that in order for cannabis to be effective as an anti-inflammatory, all of the cannabinoids found in the plant must be present, creating what is known as the Entourage Effect. While there is plenty of anecdotal evidence that cannabis holds anti-inflammatory properties, the true cause of the mode of action remains unknown. Our mission is to research this very question and identify compounds within the plant that cause a positive reaction in reducing inflammation in the body.”
Through the Company’s research division, Juva has already identified two proprietary compounds they believe may hold this potential: JUVA-019 and JUVA-041. Inflammation is a response in the body to signal potential danger or damage to organs. Inflammation can be either short-lived (acute) or long-lasting (chronic), with underlying triggers such as cancer, heart disease, asthma, and arthritis. According to recent estimates by Rand Corporation, in 2014 nearly 60% of Americans had at least one chronic condition, 42% had more than one and 12% of adults had 5 or more chronic conditions causing inflammation -- and worldwide, 3 of 5 people die due to chronic inflammatory diseases. The global anti-inflammatory therapeutics market is estimated to reach USD $191.4 billion by 2027, as reported by Fortune Business Insights.
Where many companies are conducting researching on well-known cannabinoids such as CBD and THC, Juva has identified two proprietary, non-cannabinoid compounds, JUVA-019 and JUVA-041, with potentially greater anti-inflammatory properties than cannabinoids. The goal of the announced study will be to combine JUVA-019 with popular cannabinoids such as CBD and THC and to evaluate the anti-inflammatory properties when combined versus as a standalone compound.
ON BEHALF OF THE BOARD,
-Doug Chloupek-
Doug Chloupek, CEO and Founder
Juva Life Inc.
About Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRA: 4VV)
Juva Life is employing state-of-the-art science to discover, develop and commercialize safe and effective wellness and pharmaceutical products, in both the cannabis consumer segment as well as the non-cannabinoid based medical industry. The Company is successfully executing against its 2018 roadmap, initially starting with standardization of cultivation, extraction, and formulation to offer consumers reproducible benefits. Juva is building upon these natural product process chemistry skills, to now include discovery pharmacology. The Company will leverage revenue derived from its retail operations to advance its consumer and clinical development efforts of Juva-019 and Juva-041, as well as other potentially valuable non-cannabinoid bioactives with significant consumer and pharma products applications. Juva is working to bring the Cannabis market face to face with the sector’s next generation investment grade business model. Find out more at: https://juvalife.com/.
For further information, please contact:
Juva Life Investor Relations
Tel: +1 833-333-5882 (JUVA)
Email: inquiries@juvalife.com
Forward Looking Statement
This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; product development, commercialization strategy and future collaborations.
Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation, risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended December 31, 2020 under the heading “Risks and Uncertainties”. Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
Juva Life Identifies Second Molecular Compound Found in Cannabis With Significant Anti-Inflammatory Therapeutic Properties Coined JUVA-041
Juva Life Identifies Second Molecular Compound Found in Cannabis With Significant Anti-Inflammatory Therapeutic Properties Coined JUVA-041
Cannabis and Life Sciences Company Adds Second Novel Non-Cannabinoid Compound to Pharmaceutical Pipeline
VANCOUVER, British Columbia, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a life sciences portfolio company with operations in cannabis production and distribution as well as pharmaceutical research and development, announced today that it has identified a proprietary compound, JUVA-041, found in the cannabis sativa family of plants with significant anti-inflammatory properties.
Through its research division, Juva research scientists are evaluating an internally curated database of compounds found in the cannabis plant for their therapeutic benefit. The news follows the Company’s identification of non-cannabinoid compound JUVA-019, which the Company has filed a patent upon and also begun further preclinical research. In recent months, Juva has been developing a chemical library of natural and semi-synthetic non-cannabinoids found in the cannabis plant with the intention of identifying compounds with anti-inflammatory properties, with the first compound being identified as JUVA-019. Juva’s hypothesis is that the therapeutic potential of cannabis is widely known, yet the cause of the overarching medical benefits of cannabis is mostly undefined. While many speculate that cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD) interacting with the endocannabinoid system are the cause of the benefit, Juva is taking a chemical approach to the research, looking further into the compounds present in the plant beyond cannabinoids that may have the benefit. As such, the Juva research team has built an extensive database of less studied compounds that it continues to evaluate for their anti-inflammatory potential, now having two compounds in its clinical pipeline: JUVA-019 and JUVA-041.
“Juva is a unique company in that we are leveraging our cannabis expertise to vertically integrate value-building science,” said Doug Chloupek, CEO and Founder of Juva. “While we remain focused on completing the build out and monetization of our cannabis cultivation and distribution facilities, this year we have expanded the scope in which Juva operates to now include translational research and development. Our team of scientists have taken a modern learning strategy to understand how cannabis works. While the current industry focus centers on cannabinoids, our strategy breaks from this school of thought and is focused on unappreciated non-cannabinoids with significant therapeutic potential. We have now identified two non-cannabinoid compounds that may begin to explain the clinical benefits of cannabis through an anti-inflammatory mode of action. We are excited to add to our commercial efforts in cannabis a proprietary R/D platform to execute our 2018 “farm to pharma” roadmap. Through these discoveries, and the ensuing work to follow, I can proudly state that Juva is no longer simply a cannabis operator, but a full-fledged life sciences company with existing plant-touching assets paired with industry-leading scientific research.”
JUVA-019 and JUVA-041 are now designated as lead compounds. The Company plans to conduct comparative studies on the candidates to determine if combining them with other cannabinoid or non-cannabinoid compounds increases the efficacy of the anti-inflammatory mode of action. Based on those results, Juva will either move forward with the standalone compounds, or the newly discovered, more effective formulations. After said results, the candidates will be developed in a 2-prong approach. The natural chemophores will be advanced unmodified and evaluated for select applications in the consumer nutraceutical and wellness categories. In parallel, standard medicinal chemistry tools will be applied to improve upon potency and absorption, distribution, metabolism, and excretion (ADME) properties. The compounds will be advanced through a standard pharma development stage/gate plan, beginning with profiling in industry-standard in vitro and in vivo models of inflammatory disease. This profile is necessary to attract the attention of larger pharmaceutical players who may be interested in the candidates for their own pipelines. The Company anticipates initiating non-clinical development within the next 6-9 months. This combined consumer and medical strategy reduces development cost, risk, and time, and creates an opportunity for Juva to unlock shareholder value sooner than other pharmaceutical competitors.
ON BEHALF OF THE BOARD,
-Doug Chloupek-
Doug Chloupek, CEO and Founder
Juva Life Inc.
inquiries@juvalife.com
About Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRA: 4VV)
Juva Life is employing state-of-the-art science to discover, develop and commercialize safe and effective wellness and pharmaceutical products, in both the cannabis consumer segment as well as the non-cannabinoid based medical industry. The Company is successfully executing against its 2018 roadmap, initially starting with standardization of cultivation, extraction, and formulation to offer consumers reproducible benefits. Juva is building upon these natural product process chemistry skills, to now include discovery pharmacology. The Company will leverage revenue derived from its retail operations to advance its consumer and clinical development efforts of Juva-019 and Juva-041, as well as other potentially valuable non-cannabinoid bioactives with significant consumer and pharma products applications. Juva is working to bring the Cannabis market face to face with the sector’s next generation investment grade business model. Find out more at: https://juvalife.com/.
For further information, please contact:
Juva Life Investor Relations
Tel: +1 833-333-5882 (JUVA)
Email: inquiries@juvalife.com
Forward Looking Statement
This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; product development, commercialization strategy and future collaborations.
Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation, risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended December 31, 2020 under the heading “Risks and Uncertainties”. Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
